FONTANA, Calif., April 11, 2006 (PRIMEZONE) -- GEN ID Lab Services Inc. ("GEN ID") (Pink Sheets:GDLB) introduced today its proprietary "IdentiFlu" Avian Flu (H5N1) Detection System.
GEN ID has contracted S2 Biosciences, Inc ("S2"), a privately held company, to perform the testing of biological samples (from birds and/or human origin) for the presence of the H5N1 virus commonly known as the Bird Flu. Using S2's proprietary H5N1 amplification probes and modified PCR reactions, the system will amplify several regions of the H5N1 genome, thereby providing positive proof for the presence or absence of the deadly virus.
GEN ID shall retain title and full ownership of the technologies of the business and intends to brand its test results under the "IdentiFlu" name. Furthermore GEN ID will also retain all rights to the commercial usage of the intellectual property.
"Through our experience and reputable contacts in the industry, we have positioned ourselves to offer a service which will help in efficiently identifying the deadly avian virus, or bird flu. In addition to the testing, we are working on other fronts to not only detect the virus but also seek to discover potential containment solutions," said Hector A. Veron, President of GEN ID Lab Services, Inc.
Mr. Veron continued, "This last week has been very exciting for GEN ID. We look forward to the results and will notify shareholders on further developments as they become available."
About GEN ID:
GEN ID is a diversified medical testing company that seeks to provide physicians with more necessary and personalized treatment data, individualized towards patients and based on genetic screening technologies, such as SNP (Single Nucleotide Polymorphism) testing. This analysis will provide information on genetic predisposition to varies diseases, such as different forms of cancer, cardiovascular abnormalities, dermatological deceases, predicting pharmacodynamic pattern pertinent to individual drugs for individual patients. GEN ID plans to leverage its strong relationships within the genomics community to maximize its presence in the market.
This news release may include "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included or incorporated herein may constitute forward-looking statements. Although GEN ID believes that the forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. The forward-looking statements involve risks and uncertainties that may affect GEN ID's operations and financial performance. Among the factors that could cause results to differ materially are those risks discussed in GEN ID's filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-KSB.